NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA issued a draft local coverage determination last week proposing that it end coverage of Myriad Genetics' rheumatoid arthritis test Vectra DA.

Explaining its reasoning for ending coverage of Vectra DA, Palmetto cited recent studies that raise questions as to whether the test is effective in assessing disease activity in RA patients. The draft LCD also noted the lack of prospective clinical utility data on the test and the fact that it is not included in the 2015 American College of Rheumatology treatment guidelines.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.